ICEF 15

Drug Profile

ICEF 15

Alternative Names: aSMDC - Innovacell Biotechnologie GmbH; autologous Skeletal Muscle Derived Cells - Innovacell Biotechnologie GmbH; ICEF-15; NPJ 5007

Latest Information Update: 29 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innovacell Biotechnologie GmbH
  • Developer Innovacell Biotechnologie GmbH; Norgine
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Faecal incontinence

Most Recent Events

  • 29 Sep 2015 ICEF 15 is still in phase II trials for Faecal Incontinence (In the elderly, In adults) in Austria, Bulgaria, Germany, Slovenia, Sweden and the United Kingdom
  • 29 Sep 2015 Phase-II clinical trials in Faecal Incontinence (In the elderly, In adults) in Czech Republic (IM)
  • 17 Dec 2013 Innovacell and Norgine agree to co-develop ICEF 15 in Middle East, North Africa, and Southern Africa for Stress incontinence
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top